Medical Stone Expulsive Therapy for Acutely Obstructed Ureteric Calculi
Ureteric Stone of Lower Third of Ureter
About this trial
This is an interventional treatment trial for Ureteric Stone of Lower Third of Ureter
Eligibility Criteria
Inclusion Criteria: Adults male and female aged 18 to 70 years Patients who give informed consent Stone located in the distal 1/3rd of ureter (Single, unilateral and radiopaque ureteral calculus 5 to 10 mm visible on the CT-KUB± X-ray KUB within the ureter Serum creatinine level within the normal range (adult men, 0.74 to 1.35 mg/dL & 0.59 to 1.04 mg/dL) Ability to tolerate oral fluids and oral pain medication Exclusion Criteria: Patients already taking an alpha-adrenergic antagonist medication for 4 weeks Evidence of any other renal stone simultaneously present or at any location Hydronephrosis Grade 3 (Moderate) & Grade 4 (Severe) Patients with eGFR <60 ml/min/1.73m2 Signs of infection including temperature >38ºC or Urinalysis with any of the following: Positive Leukocyte Esterase, Positive Nitrates, or White Blood Cell Count >5/hfp in the setting of a positive urine culture (defined as a single isolated bacterial species population of >100,000 CFU) Patients with chronic pain already undergoing treatment with narcotic medications or drug abusers Pregnant or lactating women Patient suffering from urinary tract infection, ureteral surgery, and existing DJ stents. Clinical jaundice Any forms of anatomical obstructions in the urinary tract The previously suffering from postural hypotension Any other disease jeopardizing participation in trial and could lead to increase patient health risks History of allergic reactions with the study drugs (Silodosin or Tamsulosin)
Sites / Locations
Arms of the Study
Arm 1
Arm 2
Active Comparator
Active Comparator
Tamsulosin
Silodosin
Patients with lower ureteric stone will be randomized through permuted block randomization equally into two group. 120 patients will be on tamsulosin 0.4 mg once daily, therapy will be given for a maximum of 4 weeks.
Patients with lower ureteric stone will be randomized through permuted block randomization equally into two group. 120 patients will be on Silodosin 8 mg once daily. Therapy will be given for a maximum of 4 weeks.